Inozyme CFO Acquires 6,813 Shares Through Employee Stock Purchase Plan

Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).

Rhea-AI Filing Summary

Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).

Key transaction details:

• Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
• ESPP purchase period: April 1, 2025 - June 25, 2025
• Total shares owned after transaction: 39,701 shares
• Ownership form: Direct

This insider purchase through the ESPP demonstrates continued participation in company equity programs by a key executive officer. The transaction was executed under the company's 2020 Employee Stock Purchase Plan, which allows employees to purchase shares at a discount to market price.

Insider Trade Summary

Grant/Award: 6,813 shares

Grant/Award 1 txn

Insider Subramanian Sanjay

Role SVP, CFO & Head of BD

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,813	$0.74	$5K

Holdings After Transaction: Common Stock — 39,701 shares (Direct)

Footnotes (1)

1. F1. Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INZY shares did CFO Sanjay Subramanian purchase on June 25, 2025?

According to the Form 4 filing, CFO Sanjay Subramanian purchased 6,813 shares of INZY common stock on June 25, 2025.

What was the purchase price per share for INZY stock in the ESPP transaction?

The shares were purchased at $0.74 per share through Inozyme's Employee Stock Purchase Plan (ESPP), which represents 85% of the closing price on April 1, 2025 (the first trading day of the purchase period).

How many INZY shares does Sanjay Subramanian own after this transaction?

Following this ESPP purchase transaction, Sanjay Subramanian directly owns 39,701 shares of INZY common stock.

What position does Sanjay Subramanian hold at INZY?

Sanjay Subramanian serves as Senior Vice President (SVP), Chief Financial Officer (CFO) & Head of Business Development at Inozyme Pharma, Inc.

What was the ESPP purchase period for this INZY stock transaction?

The ESPP purchase period was from April 1, 2025 through June 25, 2025, as disclosed in the Form 4 filing's explanatory notes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/27/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Subramanian Sanjay

(Last) (First) (Middle)

C/O INOZYME PHARMA, INC.

321 SUMMER STREET SUITE 400

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inozyme Pharma, Inc. [ INZY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO & Head of BD

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		A(1)	V	6,813	A	$0.74	39,701	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

	/s/ Sanjay Subramanian	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.